Multi-Drug Resistant Nephrotic Syndrome Clinical Trials

6 recruitingLast updated: June 18, 2026

There are 6 actively recruiting multi-drug resistant nephrotic syndrome clinical trials across 1 country. Studies span Early Phase 1, Phase 1. Top locations include Hangzhou, Zhejiang, China. Updated daily from ClinicalTrials.gov.


Multi-Drug Resistant Nephrotic Syndrome Trials at a Glance

6 actively recruiting trials for multi-drug resistant nephrotic syndrome are listed on ClinicalTrialsFinder across 1 city. The largest study group is Early Phase 1 with 3 trials, with the heaviest enrollment activity in Hangzhou. Lead sponsors running multi-drug resistant nephrotic syndrome studies include The Children's Hospital of Zhejiang University School of Medicine.

Browse multi-drug resistant nephrotic syndrome trials by phase

Top cities for multi-drug resistant nephrotic syndrome trials

Treatments under study

About Multi-Drug Resistant Nephrotic Syndrome Clinical Trials

Looking for clinical trials for Multi-Drug Resistant Nephrotic Syndrome? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Multi-Drug Resistant Nephrotic Syndrome trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Multi-Drug Resistant Nephrotic Syndrome clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Early Phase 1

CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease

IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07586267
Recruiting
Early Phase 1

Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease

IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07507201
Recruiting
Phase 1

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease

IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07305116
Recruiting
Early Phase 1

Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease

Autoimmune DiseasesSystemic Lupus ErthematosusMulti-Drug Resistant Nephrotic Syndrome+1 more
The Children's Hospital of Zhejiang University School of Medicine36 enrolled1 locationNCT06792799
Recruiting
Phase 1

Study of Therapeutic Efficacy of CAR-T Cell Therapy in Patients With MDR-SRNS

CAR-T Cell TherapyMulti-Drug Resistant Nephrotic Syndrome
The Children's Hospital of Zhejiang University School of Medicine18 enrolled1 locationNCT06553898
Recruiting
Phase 1

Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cell Therapy in Patients With MDR-SRNS

CAR-T Cell TherapyMulti-Drug Resistant Nephrotic Syndrome
The Children's Hospital of Zhejiang University School of Medicine18 enrolled1 locationNCT06842589